Background The introduction of combination antiretroviral therapy and protease inhibitors
has led to reports of falling mortality rates among people infected with HIV-1. We examined …

Background Since the introduction of highly active antiretroviral therapy (HAART), little is
known about whether changes in HIV-1 mortality and morbidity rates have been sustained …

Background: Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected
patients remains unclear. Objective: To assess the prevalence of HBV (assessed as HBsAg) …

Background The clinical presentation of HIV-1 related diseases could have changed after
the introduction of highly active antiretroviral treatment (HAART). We aimed to assess …

Objectives: To describe changes in haemoglobin over time and to determine the joint
prognostic value of the current haemoglobin, CD4 lymphocyte count and viral load among …

Objective To assess hepatitis C virus (HCV) antibody prevalence in the EuroSIDA cohort,
along with survival, human immunodeficiency virus (HIV)–1 disease progression, virologic …

Objectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both
HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term …

Background Risk factors for lipodystrophy in patients infected with HIV-1 treated with highly
active antiretroviral therapy (HAART) containing HIV-1 protease inhibitors are poorly …

Patients presenting late with HIV infection are at a higher risk of clinical events, are difficult to
treat and have a higher mortality compared with those who present earlier. Indeed, being …

Background Few studies have monitored late presentation (LP) of HIV infection over the
European continent, including Eastern Europe. Study objectives were to explore the impact …